; Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2011

VIEWS: 3 PAGES: 38

Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2011', provides an overview of the Thrombocythaemia Myelofibrosis therapeutic pipeline. This report provides information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis. 'Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Thrombocythaemia Myelofibrosis. - A review of the Thrombocythaemia Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocythaemia Myelofibrosis pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under developm

More Info
  • pg 1
									Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2011




    Thrombocythaemia Myelofibrosis - Pipeline Review,
                      H2 2011
                                                                                          Reference Code: GMDHC1512IDB

                                                                                          Publication Date: November 2011




Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2011                                                     GMDHC1512IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                Page(1)
Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
      Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Thrombocythaemia Myelofibrosis Overview.............................................................................................................................................................. 6
Therapeutics Development ....................................................................................................................................................................................... 7
      An Overview of Pipeline Products for Thrombocythaemia Myelofibrosis ............................................................................................................. 7
Thrombocythaemia Myelofibrosis Therapeutics under Development by Companies ................................................................................................. 9
Thrombocythaemia Myelofibrosis Therapeutics under Investigation by Universities/Institutes..................................................................................10
Mid Clinical Stage Products .....................................................................................................................................................................................11
      Comparative Analysis .......................................................................................................................................................................................11
Thrombocythaemia Myelofibrosis Therapeutics - Products under Development by Companies ...............................................................................12
Thrombocythaemia Myelofibrosis Therapeutics - Products under Investigation by Universities/Institutes.................................................................13
Companies Involved in Thrombocythaemia Myelofibrosis Therapeutics Development .............................................................................................14
      AstraZeneca PLC ..............................................................................................................................................................................................14
      Gilead Sciences, Inc. ........................................................................................................................................................................................14
      Infinity Pharmaceuticals, Inc. .............................................................................................................................................................................15
      YM BioSciences Inc. .........................................................................................................................................................................................15
      Novartis AG.......................................................................................................................................................................................................16
Thrombocythaemia Myelofibrosis - Therapeutics Assessment .................................................................................................................................17
      Assessment by Monotherapy Products .............................................................................................................................................................17
      Assessment by Route of Administration ............................................................................................................................................................18
      Assessment by Molecule Type ..........................................................................................................................................................................20
Drug Profiles ...........................................................................................................................................................................................................22
      AZD1480 - Drug Profile .....................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      IPI-926 - Drug Profile ........................................................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      LBH589 - Drug Profile .......................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24
            Mechanism of Action...................................................................................................................................................................................24
            R&D Progress .............................................................................................................................................................................................24
      CYT387 - Drug Profile .......................................................................................................................................................................................26
            Product Description ....................................................................................................................................................................................26
            Mechanism of Action...................................................................................................................................................................................26
            R&D Progress .............................................................................................................................................................................................26
      Pomalidomide - Drug Profile..............................................................................................................................................................................28
            Product Description ....................................................................................................................................................................................28
            Mechanism of Action...................................................................................................................................................................................28
            R&D Progress .............................................................................................................................................................................................28
      GS 6624 - Drug Profile ......................................................................................................................................................................................29
            Product Description ....................................................................................................................................................................................29


Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2011                                                                                                 GMDHC1512IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2011


            Mechanism of Action...................................................................................................................................................................................29
            R&D Progress .............................................................................................................................................................................................29
      CC-4047 - Drug Profile ......................................................................................................................................................................................31
            Product Description ....................................................................................................................................................................................31
            Mechanism of Action...................................................................................................................................................................
								
To top